Quantcast
Connect with us

‘Absolute robbery’: Gilead announces $3,120 price tag for COVID-19 drug developed with $70 million in taxpayer funds

Published

on

Gilead Sciences Logo (Olivier DOULIERY AFP)

Consumer advocates reacted with disgust Monday to an announcement by Gilead Sciences that it will charge U.S. hospitals around $3,120 per privately insured patient for a treatment course of remdesivir, a drug which has proven modestly effective at speeding Covid-19 recovery times.

Peter Maybarduk, director of Public Citizen’s Access to Medicines Program, called Gilead’s pricing—which works out to around $520 per dose for non-government buyers like hospitals—”an offensive display of hubris and disregard for the public” and slammed the Trump administration for failing to ensure that the price of a drug developed with substantial taxpayer support is affordable for all.

ADVERTISEMENT

Maybarduk pointed to Institute for Clinical and Economic Review research showing Gilead could still make a profit by pricing remdesivir at $310 per course.

“Gilead has priced at several thousand dollars a drug that should be in the public domain. For $1 per day, remdesivir can be manufactured at scale with a reasonable profit,” Maybarduk said in a statement. “Gilead did not make remdesivir alone. Public funding was indispensable at each stage, and government scientists led the early drug discovery team. Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration.”

Public Citizen estimated in a May report that U.S. taxpayers contributed at least $70.5 million to the development of remdesivir.

ADVERTISEMENT

Shortly after Gilead’s announcement, the U.S. Health and Human Services Department said it reached an agreement with the pharmaceutical giant to purchase more than 500,000 treatment courses of remdesivir for American hospitals.

The Wall Street Journal reported that the United States is “the only developed country where Gilead will charge two prices”—one for government buyers ($390 per dose) and one for non-government buyers like hospitals ($520 per dose). The typical remdesivir treatment course consists of around six doses.

Unlike the U.S., the Journal notes, the governments of other advanced nations “negotiate drug prices directly with drugmakers.”

ADVERTISEMENT

Rep. Lloyd Doggett (D-Texas), chair of the House Ways and Means Health Subcommittee, said in a statement that “Trump’s refusal to stop pandemic profiteering with a stroke of a pen is a green light to other manufacturers to exploit this tragedy.”

Doggett said he is pressuring the Trump administration and Gilead to disclose the details of their agreement, including the sum the government paid for the 500,000 treatment courses of remdesivir.

ADVERTISEMENT

On Twitter, Sen. Bernie Sanders (I-Vt.) condemned Gilead’s price-tag as “beyond disgusting.”

“Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic,” said Sanders. “Coronavirus treatment must be free to all.”


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Breaking Banner

Dennis Quaid to star in Trump’s $300 million ad campaign against COVID ‘despair’: report

Published

on

Americans should expect to see more of actor Dennis Quaid during television commercial breaks, according to a new report by Politico.

"The health department is moving quickly on a highly unusual advertising campaign to 'defeat despair' about the coronavirus, a $300 million-plus effort that was shaped by a political appointee close to President Donald Trump and executed in part by close allies of the official, using taxpayer funds," Politico's Dan Diamond reported Friday.

Continue Reading

2020 Election

Lincoln Project likens Lindsey Graham to an abused dog for being ‘violently out-fundraised’ in South Carolina re-election campaign

Published

on

Sen. Lindsey Graham (R-SC) is facing a huge fundraising shortage -- despite being an incumbent Republican senator running in South Carolina.

As he's been trailing Democrat Jaime Harrison in fundraising, Graham has repeatedly gone on Fox News to beg for donations.

“My opponent will raise almost $100 million in the state of South Carolina,” Graham complained to Fox and Friends on Thursday.

Continue Reading
 

Breaking Banner

Trump has selected Judge Amy Coney Barrett to replace RBG on the Supreme Court: NYT

Published

on

President Donald Trump is to announce on Saturday that he will nominate Judge Amy Coney Barrett as an Associate Justice on the United States Supreme Court.

"President Trump has selected Judge Amy Coney Barrett, the favorite candidate of conservatives, to succeed Justice Ruth Bader Ginsburg and will try to force Senate confirmation before Election Day in a move that would significantly alter the ideological makeup of the Supreme Court for years," New York Times chief White House correspondent Peter Baker reported Friday.

"Mr. Trump plans to announce on Saturday that she is his choice, according to people close to the process who asked not to be identified disclosing the decision in advance. The president met with Judge Barrett at the White House this week and came away impressed with a jurist that leading conservatives told him would be a female Antonin Scalia, referring to the justice who died in 2016 and for whom Judge Barrett clerked," the newspaper explained.

Continue Reading
 
 
Democracy is in peril. Invest in progressive news. Join Raw Story Investigates for $1. Go ad-free. LEARN MORE